Kiniksa News - LARVOL Sigma

«123 4 5 6 7 8 »

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Rilonacept for Refractory Pericarditis Following Immune Checkpoint Inhibitor Therapy: A Case Report (Zone 4, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_5474;
Given the refractory nature of the recurrent pericarditis, the decision was made to reintroduce prednisone therapy, which led to substantial symptomatic improvement...Rilonacept was added due to the refractory nature of her symptoms with steroid taper. It led to sustained improvement in pain, and steroids were successfully tapered.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Successful Treatment of Recurrent Pericarditis With Rilonacept in the Setting Of ATRA/ATO Use in Acute Promyelocytic Leukemia (Zone 4, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_5472;
Management is complicated and requires multi-disciplinary care. Our case illustrates that rilonacept may be considered as an alternative to corticosteroids in the treatment of recurrent pericarditis in a patient with a hematologic malignancy.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Cardiac Magnetic Resonance Imaging Paralleled Recurrent Pericarditis Clinical Response to Rilonacept Treatment Over 18 Months: A RHAPSODY Subgroup Analysis (Zone 2, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_5216;
Negative/trace LGE at 18MDM while on treatment did not predict absence of pericarditis recurrence upon subsequent rilonacept suspension in this size-limited subgroup. Larger prospective studies examining CMR parameters in guiding RP treatment duration decisions and informing associated clinical outcomes are warranted.

|||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa
Neutrophil to Lymphocyte Ratio: A Marker of Inflammation in Pericardial Disease (Zone 4, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_4689;
A normal range of NLR is between 1-2, with values higher than 3.0 and below 0.7 considered pathological. Our case highlights the importance of NLR as a diagnostic and prognostic marker of pericardial disease.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Recurrent Pericarditis Following Atrial Fibrillation Ablation: Unmasking Latent Tuberculosis Infection (Zone 2, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_4297;
He received high-dose aspirin, prednisone, and colchicine for recurrent pericarditis...He experienced a 4th episode of pericarditis while tapering off prednisone, and restarted prednisone, Ibuprofen, and colchicine...After completing 6-months of Rifampin and Rilonacept, he had significant improvement and no further recurrences on 1 year follow up...However, investigation revealed underlying latent pericardial TB infection. Appropriate treatment led to complete resolution without sequelae.

|||||||||| KPL-404 / Kiniksa, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Immune Monitoring of The First Cardiac Xenotransplant From Genetically engineered pig to a Human (Indigo H) - Aug 9, 2023 - Abstract #IPITAIXACTRMS2023IPITA_IXA_CTRMS_521;
Induction included ATG (after xTX), Rituxan (one dose only), C1 esterase, and costimulation blockade with humanized anti-CD40 (KPL404) antibody. Our study demonstrates that immune monitoring accurately reflects the immune response status of the recipient after cardiac xTX and continuous monitoring will aid in the early detection of rejection even and allow effective intervention.

|||||||||| Review, Journal: Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review. (Pubmed Central) - Jul 16, 2023
The study revealed a low rate of active TB in pediatric patients using biologic therapy. Screening for LTBI before initiating biologics should be done in all patients, and treatment, in cases of positive screening, plays a critical role in preventing progression to TB disease.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: Identification of an IL-1 receptor mutation driving autoinflammation directs IL-1-targeted drug design. (Pubmed Central) - Jul 14, 2023
and IL-1?, but not IL-1Ra. Collectively, this work provides molecular insights and a potential drug for improved potency and specificity in treating IL-1-driven diseases.

|||||||||| Journal: Computational Drug Discovery in Ankylosing Spondylitis-induced Osteoporosis Based on Data Mining and bioinformatics analysis. (Pubmed Central) - Jun 5, 2023
Collectively, this work provides molecular insights and a potential drug for improved potency and specificity in treating IL-1-driven diseases. Carlumab, bermekimab, rilonacept, rilotumumab, and ficlatuzumab were first identified as the potential drugs for the treatment of AS-OP, proving the value of text mining and pathway analysis in drug discovery.

|||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal, MRI: Cardiac magnetic resonance imaging of pericardial diseases: a comprehensive guide. (Pubmed Central) - May 19, 2023
We sought to provide a summary of the clinical protocols used and an interpretation of the major CMR findings in the setting of pericardial diseases. We also discuss points that are less well clear and delineate the strengths and weak points of CMR in pericardial diseases.

|||||||||| colchicine / Generic mfg., Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa
Monotherapy: IL-1 inhibitor in pericarditis @PaulCremerMD AIRTRIP: anakinra in colchicine-res pericarditis: 2/11 recurrence vs 9/10 on PBO RHAPSODY: rilonacept: 2/30 recurrence vs 23/31 in PBO w a rapid time of action Rapid taper of other treatments down to monotherapy #ACRX23 @RheumNow (Twitter) - Apr 30, 2023

|||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, vixarelimab (RG6536) / Roche, Mitchga (nemolizumab) / Roche, Maruho, Galderma
How to treat different severity stages of chronic nodular prurigo in 2023: what are the guidelines recommending and what is new? (Level 3 - Room 327) - Apr 24, 2023 - Abstract #WCD2023WCD_2949;
Recently dupilumab has recently received approval for the treatment of moderate to severe CNPG...For example, pruritus intensity on the NRS decreased by over 60% and pruriginous lesions improved in 78% of patients treated with nemolizumab, a humanized monoclonal antibody against IL-31 receptor-A. As another monoclonal antibody, vixarelimab blocks the action of IL-31 and OSM at the OSM-receptor-

||||||||||  vixarelimab (RG6536) / Roche
New P2 trial:  A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease (clinicaltrials.gov) -  Mar 27, 2023
P2, N=290, Recruiting,  Sponsor: Genentech, Inc.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: How to Use Interleukin-1 Antagonists in Pericarditis. (Pubmed Central) - Mar 7, 2023
As another monoclonal antibody, vixarelimab blocks the action of IL-31 and OSM at the OSM-receptor- Recurrent pericarditis (RP) is one of the most common complications of pericarditis, affecting 15-30% of patients after an initial episode and >40% after a first recurrence.[1, 2] Up to 5-10% of RP patients develop multiple recurrences that are difficult to treat and refractory to conventional anti-inflammatory therapy, suggestive of refractory corticosteroid-dependent, colchicine-resistant RP.[2, 3] Several treatment options are suggested for such patients, including interleukin-1 (IL-1) antagonists, which are currently off-label for treating pericarditis in Canada.[1, 3] This paper aims to provide a focused guide to using anti-IL-1 agents (specifically anakinra and rilonacept), including practical tips from our experience.

|||||||||| Severe delayed reactions associated with anakinra, canakinumab, tocilizumab and rilonacept (Convention Center, Lobby Level, Hall 2) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1808;
In this cohort with autoinflammation, DLD, HLH, and higher fatality associate with continuing anti-IL-1/IL-6 after DRESS occurs. A limitation of the analysis is possible confounding by disease course severity.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
IS IT POSSIBLE FOR AN ATHLETE WITH RECURRENT PERICARDITIS TO EXERCISE VIGOROUSLY ON AN IL-1 BLOCKER? (Complex Clinical Cases Moderated Poster Theater 6_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_7949;
The patient was started on Rilonacept and was able to completely wean off prednisone, ibuprofen and colchicine with significant clinical improvement. We present a case of an avid runner that responded well to Rilonacept and was able to resume exercise successfully.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
LIBERALIZED EXERCISE REGIMEN IN A PATIENT WITH SEVERE RECURRENT PERICARDITIS AFTER CLINICAL REMISSION ON RILONACEPT (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_4998;
We present a case of an avid runner that responded well to Rilonacept and was able to resume exercise successfully. In patients with severe recurrent pericarditis that respond well to Rilonacept therapy, liberalization of exercise is achievable and should be approached with shared decision-making.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
A CLINICAL ROLLER-COASTER: TRAUMATIC MYOPERICARDITIS FOLLOWING AN AMUSEMENT PARK RIDE (eAbstract Site) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_4859;
Prednisone was initiated... Persistent or recurrent pericardial symptoms from PCIS is rare, multimodality imaging may aid in guiding therapy, and IL-1 blockade may have a role in managing recurrent symptoms.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
A RARE CASE OF PERICARDITIS CAUSED BY PECTUS EXCAVATUM SURGERY (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_4841;
Pericarditis is a rare complication of Nuss procedure. IL-1 inhibitors can be used in corticosteroid-dependent colchicine-resistant cases and removal of the Nuss bars provides definitive management.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
A RARE CASE OF CARDIAC SARCOIDOSIS MANIFESTING AS CHRONIC RECURRENT PERICARDITIS (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_4776;
Cardiac MRI is an important diagnostic modality. IL-1 inhibitors may provide improved treatment of sarcoid-induced pericardial inflammation.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
SARS-COV-2 AND MRNA VACCINE-ASSOCIATED RECURRENT PERICARDITIS TREATED WITH RILONACEPT (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_1477;
This case shows that rilonacept is an effective treatment for SARS-CoV-2 and mRNA vaccine-associated pericarditis, and implies that cytokine dysregulation is a significant contributor to its pathogenesis. Furthermore, the case suggests that rilonacept may prevent recurrence of pericarditis in a susceptible individual acutely diagnosed with SARS-CoV-2

|||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa
OROPHARYNGEAL TUMOR CELLS INDUCE COX-2 EXPRESSION IN PERIPHERAL BLOOD MONOCYTES BY SECRETION OF IL-1ALPHA (207A) - Jan 1, 2023 - Abstract #IPVC2023IPVC_418;
HPV-16+ OPC patients have higher plasma PGE2 levels than HPV- patients (p<0.01). COX-2 mRNA is elevated in patients' monocytes compared to monocytes from controls (p<0.01).

|||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa
Retrospective data, Review, Journal: Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis. (Pubmed Central) - Dec 13, 2022
These outcomes were most prominent with the use of rilonacept and anakinra in the trial treatment. Rilonacept and anakinra are valuable options in case of recurrent pericarditis refractory to conventional drugs.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: Rilonacept and Other Interleukin-1 Inhibitors in the Treatment of Recurrent Pericarditis. (Pubmed Central) - Nov 19, 2022
Many of these patients are refractory to colchicine, and become corticosteroid-dependent...Anakinra is a recombinant IL-1 receptor antagonist that blocks the action of circulating IL-1α and IL-1β...Canakinumab is a selective human monoclonal antibody against IL-1β, and data on its use in recurrent pericarditis is scarce. Several questions regarding IL-1 inhibitor therapy, such as the duration of treatment and the recommended tapering protocols, as well as their use in special populations like pregnant or lactating women, remain unanswered and need to be addressed in future studies.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: What is rilonacept's role in treating recurrent pericarditis? (Pubmed Central) - Nov 1, 2022
A loading dose of rilonacept is administered subcutaneously (SQ), along with weekly SQ maintenance dosing, which can be self-administered. Rilonacept is indicated for the treatment of recurrent pericarditis and reduction in risk of recurrence in patients age 12 years and older who have an elevated C-reactive protein level and significant disease burden.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal, Monotherapy: Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis. (Pubmed Central) - Nov 1, 2022
P3
Rilonacept is indicated for the treatment of recurrent pericarditis and reduction in risk of recurrence in patients age 12 years and older who have an elevated C-reactive protein level and significant disease burden. Rapid discontinuation of oral RP therapies while transitioning to rilonacept monotherapy was feasible without triggering pericarditis recurrence.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
P3 data, Journal, HEOR: Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY. (Pubmed Central) - Oct 25, 2022
P3
These findings extend prior rilonacept efficacy results, demonstrating improvements in patient-reported health-related quality of life, sleep, pain, and global symptom severity while on treatment. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03737110.

|||||||||| Journal: Bioinformatics analysis to identify intersection genes, associated pathways and therapeutic drugs between COVID-19 and Oral candidiasis. (Pubmed Central) - Oct 11, 2022
In this study, TNF, IL1B, IFNG, CSF2, ELANE, CCL2, MMP9, CXCR4, and IL1A were potentially key genes involved in the treatment of OC/COVID-19. Taken together five drugs and twenty herb ingredients were identified as potential therapeutic agents for OC/COVID-19 treatment and management.

||||||||||  vixarelimab (RG6536) / Roche
Enrollment closed:  KPL-716-C201: Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis (clinicaltrials.gov) -  Sep 28, 2022
P2a/b, N=190, Active, not recruiting,  Sponsor: Kiniksa Pharmaceuticals, Ltd.
Taken together five drugs and twenty herb ingredients were identified as potential therapeutic agents for OC/COVID-19 treatment and management. Recruiting --> Active, not recruiting

|||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa, Ilaris (canakinumab) / Novartis
Clinical data, Review, Journal: IL-1 inhibition in familial Mediterranean fever: clinical outcomes and expectations. (Pubmed Central) - Sep 20, 2022
Nevertheless, there are no controlled trials showing the efficacy of anti-IL-1 agents in preventing amyloidosis or their safety in pregnancy. Therefore, it is still needed to give IL-1 blockers with concomitant colchicine in its tolerable dose effective in preventing amyloidosis (1.5 mg daily in adult).

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and mRNA Vaccinations: Experience From Phase 3 Rhapsody Long-Term Extension (Zone 2, Science and Technology Hall, Level 3; Poster Board no. 2227) - Sep 18, 2022 - Abstract #AHA2022AHA_7251;
In patients on rilonacept in this study, although numbers are small, vaccination reduced COVID-19 events, pericarditis recurrence was not increased by vaccination or disease, and no pericarditis recurrences occurred during rilonacept treatment. One pericarditis recurrence occurred remotely after rilonacept suspension in the peri-COVID-19 period.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Prolonged Rilonacept Treatment in Rhapsody Long-Term Extension Provided Persistent Reduction of Pericarditis Recurrence Risk (Zone 2, Science and Technology Hall, Level 3; Poster Board no. 2223) - Sep 18, 2022 - Abstract #AHA2022AHA_7250;
Concomitant oral medications during LTE: 22% NSAIDS, 20% colchicine, 0% corticosteroids, 43% none. Continued rilonacept treatment resulted in continued treatment response, whereas treatment suspension at 18 months may be associated with pericarditis recurrence.

|||||||||| KPL-404 / Kiniksa
Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1585;
KPL-404 demonstrated prolonged absorption/excretion capable of suppressing TDAR for extended periods allowing for use of extended dosing intervals irrespective of IV or SC dosing. These analyses supported the design of the ongoing Phase 2 study assessing the efficacy and safety KPL-404 in RA.Figure 1.

|||||||||| FDA event, Review: Review of IL-1 inhibitors in recurrent idiopathic pericarditis. While Rilonacept is FDA approved (320 mg x1 then 160 mg sc/wk), anakinra (2 mg/kg/d or 100 mg/d), canakinumab and colchicine are used https://t.co/j00yWpBbq3 (Twitter) - Sep 4, 2022

|||||||||| FDA event, Review: Review of IL-1 inhibitors in recurrent idiopathic pericarditis. While Rilonacept is FDA approved (320 mg x1 then 160 mg sc/wk), anakinra (2 mg/kg/d or 100 mg/d), canakinumab and colchicine are used https://t.co/EQJV4qTFPj (Twitter) - Aug 30, 2022

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Clinical, Journal: Anti-interleukin-1 agents for pericarditis: a primer for cardiologists. (Pubmed Central) - Aug 24, 2022
For patients with corticosteroid-dependent and colchicine-resistant recurrent pericarditis with evidence of systemic inflammation, as evidenced by elevated C-reactive protein, the efficacy and safety of anakinra (2 mg/kg/day up to 100 mg/day subcutaneously usually for at least 6 months, then tapered) and rilonacept (320 mg subcutaneously for the first day followed by 160 mg subcutaneously weekly) have been clearly demonstrated in observational studies and randomized controlled clinical trials...The most common reported side effect is injection site reactions (>50% of patients). In this article, we describe the historical and pathophysiological background and provide a comprehensive review of these agents, which appear to be the most significant advance in medical therapy of recurrent pericarditis in the last 5 years.

|||||||||| mavrilimumab (KPL-301) / Kiniksa
13S112: Molecular Mechanisms of Novel Therapeutic Agents in Vasculitis (Terrace Ballroom IV) - Aug 22, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_443;
Several new therapeutics are in clinical trials for giant cell arteritis, including anti-GM-CSF receptor, mavrilimumab, and JAK-STAT inhibitors...New therapeutics for IgG4 vasculitis will also be discussed.. Learning Objectives: Define the anti-inflammatory molecular mechanisms of anti-GM-CSF receptor in giant cell arteritis Review the new findings of a tissue resident T cell population driving smoldering large vessel vasculitis amendable to JAK-STAT inhibition Discuss the molecular mechanism of several therapeutic agents in IgG4 clinical trials

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Rilonacept for Refractory Pericarditis Following Immune Checkpoint Inhibitor Therapy: A Case Report (Zone 4, Science and Technology Hall, Level 200) - Aug 20, 2022 - Abstract #AHA2022AHA_5474;
Learning Objectives: Define the anti-inflammatory molecular mechanisms of anti-GM-CSF receptor in giant cell arteritis Review the new findings of a tissue resident T cell population driving smoldering large vessel vasculitis amendable to JAK-STAT inhibition Discuss the molecular mechanism of several therapeutic agents in IgG4 clinical trials Abstract is embargoed at this time.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Successful Treatment of Recurrent Pericarditis With Rilonacept in the Setting Of ATRA/ATO Use in Acute Promyelocytic Leukemia (Zone 4, Science and Technology Hall, Level 200) - Aug 20, 2022 - Abstract #AHA2022AHA_5472;
Abstract is embargoed at this time. Abstract is embargoed at this time.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Cardiac Magnetic Resonance Imaging Paralleled Recurrent Pericarditis Clinical Response to Rilonacept Treatment Over 18 Months: A RHAPSODY Subgroup Analysis (Zone 2, Science and Technology Hall, Level 200) - Aug 11, 2022 - Abstract #AHA2022AHA_5216;
Abstract is embargoed at this time. Abstract is embargoed at this time.

|||||||||| Characterization of Pulmonary Vein Reconnection in Repeat Procedures After After Initial Cryoballoon Ablation Identified With High Density Mapping (Zone 2, Science and Technology Hall, Level 200) - Aug 11, 2022 - Abstract #AHA2022AHA_4322;
Abstract is embargoed at this time. Abstract is embargoed at this time.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Review, Journal: Recurrent Pericarditis: a Stubborn Opponent Meets New Treatments in 2022. (Pubmed Central) - Jul 31, 2022
These advances offer not only new tools in our fight against this disease, but also the promise of earlier intervention and attenuation of disease morbidity. As our experience with these new agents expands, we can address questions about the ideal timing of introduction of anti-IL-1 therapy and duration of therapy and better understand the potential side effect profile.

|||||||||| Review: Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders. (Pubmed Central) - Jul 27, 2022
This systematic review of IL-1-targeting biologics summarizes the current state of research, safety, and clinical efficacy of anakinra, bermekimab, canakinumab, gevokizumab, and rilonacept in treating immune-mediated disorders. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42021228547.

||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion:  RHAPSODY: Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis (clinicaltrials.gov) -  Jul 26, 2022
P3, N=86, Completed,  Sponsor: Kiniksa Pharmaceuticals (UK), Ltd.
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42021228547. Active, not recruiting --> Completed

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Review, Journal: Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis. (Pubmed Central) - Jul 15, 2022
Both anakinra and rilonacept have demonstrated efficacy in randomized trials of patients with recurrent pericarditis. The aim of the current review is to explain the biological rationale for interleukin-1 antagonists in recurrent pericarditis, highlight supporting clinical evidence, and emphasizing future areas of investigation.

|||||||||| Journal: Recent advances in the diagnosis and therapy of large vessel vasculitis. (Pubmed Central) - Jul 2, 2022
On the other hand, tocilizumab may be used to treat both diseases. Promising targeted therapies evaluated in ongoing clinical trials include, for example, anti-IL-12/23 (ustekinumab), anti-IL-17 (secukinumab), anti-IL-1 (anakinra), anti-IL-23 (guselkumab), anti-cytotoxic T-lymphocyte antigen 4 (abatacept), Janus kinase inhibitors (tofacitinib and upadacitinib), anti-granulocyte / macrophage colony-stimulating factor (mavrilimumab), and endothelin receptor (bosentan) therapies.

|||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
A case of corticosteroid-dependent colchicine-resistant pericarditis controlled with Rilonacept. (Clinical Case Corner) - Jun 15, 2022 - Abstract #ESC2022ESC_3726;

|||||||||| KPL-404 / Kiniksa
DOSE-DEPENDENT SUPPRESSION OF T CELL-DEPENDENT ANTIBODY RESPONSE IN HEALTHY VOLUNTEERS BY KPL-404, AN ANTI-CD40 MONOCLONAL ANTIBODY, SUPPORTS CHRONIC DOSING STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS () - May 24, 2022 - Abstract #EULAR2022EULAR_3343;
KPL-404 demonstrated prolonged absorption/excretion capable of suppressing TDAR for extended periods allowing for use of extended dosing intervals irrespective of IV or SC dosing. These analyses supported the design of the ongoing Phase 2 study assessing the efficacy and safety KPL-404 in RA.

|||||||||| KPL-404 / Kiniksa
SAFETY, TOLERABILITY, PHARMACOKINETICS, RECEPTOR OCCUPANCY, AND SUPPRESSION OF T-CELL-DEPENDENT ANTIBODY RESPONSE IN A PHASE 1 STUDY WITH KPL-404, AN ANTI-CD40 MONOCLONAL ANTIBODY () - May 24, 2022 - Abstract #EULAR2022EULAR_3322;
The safety and tolerability data and the PK/PD profile of KPL-404 support further investigation of KPL-404 in a broad range of autoimmune diseases, including rheumatoid arthritis. These data support the optionality for studying chronic KPL-404 dosing in patients with subcutaneous and/or intravenous administration.

|||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa, Ilaris (canakinumab) / Novartis
Clinical, Review, Journal: Conventional and Novel Therapeutic Options in Children with Familial Mediterranean Fever: A Rare Autoinflammatory Disease. (Pubmed Central) - May 19, 2022
Other conventional or biological therapeutic options do not currently have appropriate evidence-based support, except for some specific clinical presentations (e.g., arthritis). In this review, we discuss the biological basis and the clinical evidence for the current pharmacological treatment options available for pediatric FMF.



	Diseases Companies Products Productz Mechanisms of Action Sites